Released: Monday 17th August 2020

Bamburgh Capital Limited is pleased to announce that MIJ has secured commitments from two prestigious Japanese Pharmaceutical companies totalling 20 billion Yen, approximately 20 million dollars. Over the next twelve months, they intend to target a total fund of 50-60 million dollars.

• Nippon Shinyaku is a prominent Japanese pharmaceutical company listed on the Tokyo stock exchange with a market capitalisation of $5.7 billion. They have both a pharmaceutical and nutraceutical division.
• Torii Pharmaceutical is a prominent Japanese pharmaceutical company also listed on the Tokyo stock exchange with a market capitalisation just below $1 billion. It is a subsidiary of Japan Tobacco Inc which has a market capitalisation of approximately $40 billion.

MIJ will provide support to accelerate commercialisation in Japanese markets including marketability evaluations, developing regulatory strategies, promoting clinical trials and introductions to experts and partners companies. In addition and if appropriate, MIJ will also be able to help companies explore licensing and other commercial agreements with Nippon Shinyaku and Torii Pharmaceuticals.

Investment activity is expected to commence in early September 2020 and will broadly be focused on the areas of Pharmaceutical, Medical Devices and Digital Health.

Further details of the fund can be found in the official press release.